全文获取类型
收费全文 | 6969篇 |
免费 | 325篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 78篇 |
儿科学 | 125篇 |
妇产科学 | 80篇 |
基础医学 | 952篇 |
口腔科学 | 115篇 |
临床医学 | 428篇 |
内科学 | 1705篇 |
皮肤病学 | 70篇 |
神经病学 | 611篇 |
特种医学 | 243篇 |
外科学 | 1143篇 |
综合类 | 22篇 |
预防医学 | 230篇 |
眼科学 | 98篇 |
药学 | 597篇 |
中国医学 | 32篇 |
肿瘤学 | 796篇 |
出版年
2023年 | 16篇 |
2022年 | 42篇 |
2021年 | 79篇 |
2020年 | 35篇 |
2019年 | 59篇 |
2018年 | 72篇 |
2017年 | 77篇 |
2016年 | 81篇 |
2015年 | 83篇 |
2014年 | 91篇 |
2013年 | 162篇 |
2012年 | 221篇 |
2011年 | 252篇 |
2010年 | 170篇 |
2009年 | 146篇 |
2008年 | 245篇 |
2007年 | 312篇 |
2006年 | 312篇 |
2005年 | 324篇 |
2004年 | 298篇 |
2003年 | 334篇 |
2002年 | 334篇 |
2001年 | 312篇 |
2000年 | 333篇 |
1999年 | 332篇 |
1998年 | 96篇 |
1997年 | 85篇 |
1996年 | 76篇 |
1995年 | 79篇 |
1994年 | 85篇 |
1993年 | 80篇 |
1992年 | 231篇 |
1991年 | 243篇 |
1990年 | 215篇 |
1989年 | 200篇 |
1988年 | 199篇 |
1987年 | 171篇 |
1986年 | 182篇 |
1985年 | 144篇 |
1984年 | 94篇 |
1983年 | 76篇 |
1982年 | 43篇 |
1981年 | 29篇 |
1980年 | 27篇 |
1979年 | 77篇 |
1978年 | 36篇 |
1977年 | 25篇 |
1976年 | 22篇 |
1975年 | 11篇 |
1969年 | 10篇 |
排序方式: 共有7325条查询结果,搜索用时 0 毫秒
61.
62.
Soluble interleukin 2 receptor (sIL2R) level in the serum of 10 patients with drug-induced allergic hepatitis (DIAH) were quantified with a solid-phase enzyme immunoassay using two monoclonal antibodies against the receptor. The sIL2R levels in patients with DIAH were significantly higher than in 15 normal subjects (p less than 0.01). The high sIL2R levels observed during the florid stage of DIAH returned to normal during convalescence (p less than 0.05). SIL2R from the serum of DIAH patients was found to bind to a recombinant IL2 affinity column. It seems likely that sIL2R inhibits the hyper-immune reaction that occurs in drug allergies due to bind IL2. But, we have no data that sIL2R inhibits actually the biological activity of IL2. 相似文献
63.
64.
Oowaki H Matsuda S Sakai N Ohta T Iwata H Sadato A Taki W Hashimoto N Ikada Y 《Biomaterials》2000,21(10):1039-1046
Endovascular neurosurgery is now becoming available as one of strategies for the treatment of cerebro-spinal arterio-venous malformations and aneurysms. For this treatment, a microcatheter is advanced into or close to a lesion and then an embolic material is administered through it to obliterate the lesion. N-butyl-2-cyanoacrylate (NBCA) has preferentially been used as an embolic material in Europe and America. However, its exceptionally strong adhesive force sometimes causes adhesion between the tip of the microcatheter and the artery. In this study, a new non-adhesive cyanoacrylate, isostearyl-2-cyanoacrylate (ISCA), was developed. It carries a long hydrophobic side isostearyl group with lower reactivity and adhesion than other cyanoacrylates. Its polymerization rate is, however, too low to obliterate a vascular lesion with a rapid blood flow. To increase the polymerization rate. ISCA was mixed with NBCA. As a result, the adhesive force of the mixture became extremely low, compared with that of NBCA. The viscosity of the mixture was low enough to allow its' use as an embolic material. Tissue reactions against the mixture was milder than those against NBCA. Radio-angiography became possible by mixing further with Lipiodol. The evaluation of this new embolic material with a rabbit renal artery showed that the obliteration effect of the mixture of ISCA and NBCA was excellent to use as an embolic material for clinical applications. 相似文献
65.
Hino M Yamane T Ohta K Kubota H Katagami T Tatsumi N 《Rinsho byori. The Japanese journal of clinical pathology》2000,48(8):689-693
Measurement of complete blood cell count and white blood cell differentiation is an essential laboratory test and the most important screening test for hematological malignancy. Recently, several automated blood cell analyzers have been developed to improve accuracy and precision. When flag messages generated in the presence of morphological abnormalities of the samples are displayed, manual revision is necessary. In our laboratory, the manual revision rate has been 35-40%. Therefore blood cell analyzers are useful in screening for abnormalities as well as greatly reducing expensive and time-consuming manual differential procedures. In addition, automated blood cell analyzers can provide several types of useful information including the leukocyte distribution scattergram. However, most such information is not utilized in the clinical field. In the future, a total hematological analysis system will be constructed so that all information provided by automated blood cell analyzer and by manual methods are available. 相似文献
66.
Association between HLA and Japanese patients with rheumatoid arthritis 总被引:12,自引:0,他引:12
N Ohta Y K Nishimura K Tanimoto Y Horiuchi C Abe Y Shiokawa T Abe M Katagiri T Yoshiki T Sasazuki 《Human immunology》1982,5(2):123-132
Japanese patients with rheumatoid arthritis (RA) were observed to have a statistical association with HLA-DR4, MT3. Strong association between the clinical severity of RA and HLA was also observed. Male patients had a stronger association with HLA than female patients. Males are more resistant to RA than females. This suggested that the threshold of liability for RA is higher in males than in females. Japanese patients with RA with systemic vasculitis were negative for HLA-Bw44 and had antilymphocytotoxic autoantibody, indicating that RA with systemic vasculitis is different in etiology from RA without systemic vasculitis. 相似文献
67.
Kiyoji Kimura Ryuzo Ohno Ichita Amaki Kenichi Hattori Yutaka Hirota Akira Hoshino Michito Ichimaru Munemoto Ito Ikuo Kimura Tadashi Maekawa Toru Masaoka Toru Nakamura Makoto Ogawa Masao Oguro Kazuo Ohta Shigeyuki Osamura Masanori Shimoyama Fumimaro Takaku Yoshiro Uzuka Kazumasa Yamada 《Medical oncology (Northwood, London, England)》1986,3(1):15-24
A phase I study ofN 4-behenoyl-1-β-d-arabinofuranosylcytosine (BHAC) was conducted in 66 patients, 41 with solid tumors and 25 with hematological malignancies. The patients received either a 2-h single intravenous (i.v.) drip infusion (Schedule 1) or consecutive daily 2-h i.v. infusions (Schedule 2). In Schedule 1 the daily dose was initiated with 1.5 mg kg?1 which was escalated up to 7 mg kg?1. Side-effects were mild, and included nausea, vomiting, epilation, and hot flushes. Because of the presence of the solvent vehicle, HCO-60 and in consideration of the mechanism of action of BHAC, the dose escalation was stopped at 7 mg kg?1. In Schedule 2, the daily dose was started with 1.5 mg kg?1 which was escalated up to 8 mg kg?1 and given for 2–16 days. Myelosuppression was found to be dose-limiting toxicity. The maximum tolerated dose (MTD) in patients with non-hematological solid tumors was assumed to be 5 mg kg?1 daily × 5 days. The plasma disappearance curve of BHAC looked biphasic, and when 4 mg kg?1 of BHAC were administered the half-lives of the initial phase (t 1/2α) and the second phase (t 1/2β) were calculated as 0.798 and 5.76 h respectively. In Schedule 2 complete remission was observed in 5 out of 21 patients with acute leukemia, one partial remission in Hodgkin’s disease, and one 1-B response (Karnofsky) in thyroid papillary adenocarcinoma. 相似文献
68.
Takanori Abe Satoshi Saito Misaki Iino Tomomi Aoshika Yasuhiro Ryuno Tomohiro Ohta Mitsunobu Igari Ryuta Hirai Yu Kumazaki Yasuhiro Ebihara Mitsuhiko Nakahira Masashi Sugasawa Shin-ei Noda Shingo Kato 《Journal of radiation research》2021,62(1):104
The purpose of this study was to describe the results of definitive radiotherapy (RT) with concurrent chemotherapy for maxillary sinus carcinomas (MSCs) with neck lymph node metastasis to clarify its limitation. Local control (LC), progression-free survival (PFS) and overall survival (OS) rates were calculated using the Kaplan–Meier method and were compared between subgroups using the log rank test. Toxicity was classified using common terminology criteria of adverse events version 5.0. Eighteen patients with inoperable MSC with neck lymph node metastasis including 12 men and 6 women with a median age of 67 years were analyzed. The histologic diagnoses were as follows: 16 patients had squamous cell carcinomas and 2 had other histology. Four patients had stage T3 MSC, 6 had T4a and 8 had T4b. Among 18 patients, 7 received concurrent systemic chemotherapy and 11 received selective arterial chemo-infusion. The median follow-up period was 17 months. The 2-year LC, PFS and OS rates for the entire cohort were 34, 31 and 46%, respectively. No significant differences were observed for LC, PFS and OS rates between systemic chemotherapy and selective arterial chemo-infusion cohorts. Grade 3 or higher acute toxicity, including both non-hematological and hematological, was observed in nine patients (50%), while no grade 3 or higher late toxicity was observed. In conclusion, we described the results of definitive RT for MSCs with neck lymph node metastasis. Local recurrence of primary tumor was a frequent pattern of failure and it should be addressed in future study. 相似文献
69.
K Yoshida R Abe S Itoh T Taguchi J Ohta T Morimoto T Ishida H Tashiro M Ogita C Kido 《Japanese journal of clinical oncology》1990,20(4):374-379
In a nation-wide collaborative study on mass screening for breast cancer, we collected 152 cases of interval breast cancer diagnosed at 35 hospitals or clinics distributed throughout Japan. The definition of interval breast cancer used in the present study is "breast cancer cases which were diagnosed as having 'no malignant findings' in a previous screening for breast cancer but subsequently diagnosed as 'breast cancer' at a hospital or medical clinic within two years of the previous screening." The clinical stages and prognoses of these interval cancer were analyzed and compared with those of other breast cancers detected through mass screening and in outpatient clinics. In the clinical staging of interval breast cancer, Tis (non infiltrating cancer) accounted for only 2.1%, compared to 8.0% in cases detected through mass screening. At stage I 43.4% were interval breast cancers compared to 32.9% breast cancers detected through mass screening and 25.4% diagnosed in outpatient clinics. The stage differences between interval breast cancers and breast cancers detected through mass screening were not statistically significant. Five-year survival rates were 85.6% for interval breast cancers, 91.7% for breast cancers detected through mass screening and 84.7% for breast cancers diagnosed in outpatient clinics. Ten-year survival rates were 75.9, 80.5 and 78.1%, respectively, suggesting the interval breast cancer cases to show a similar prognosis to that of breast cancer cases diagnosed in outpatient clinics. The differences in five- and 10-year survival rates among the three groups were not statistically significant. From the present study we were not able to confirm the general belief of interval cancer being more aggressive in nature and showing a poorer prognosis than cancer detected through periodic screening. The reasons for this are discussed. 相似文献
70.
Ohta T Fukuda M Arima K Kawamoto H Hashizume R Arimura T Yamaguchi S 《Breast cancer (Tokyo, Japan)》1997,4(1):17-24
Cyclins and cyclin-dependent kinases may reflect the status of cell proliferation in cancer tissues. The authors sought to
determine whether cdc2 and cyclin D1 are expressed in breast cancer and are useful as prognostic factors. Accumulation of
cdc2 and cyclin D1 proteins was examined in 88 cases of breast cancer using immunoblotting techniques and correlations with
clinicopathological factors and prognoses were investigated. Cdc2 and cyclin D1 proteins were observed in 27.3% and 75.0%
of breast cancers studied, respectively. The incidence of lymph node metastasis was significantly high in cdc2/cyclin D1-double
positive group and low in double negative group. On the other hand, the incidence of estrogen receptor (ER) negative cases
was significantly higher in the cdc2-positive/cyclin D1-negative group. Relapse-free survival times of cdc2-positive cases
were significantly shorter than those of cdc2-negative cases. The relapse-free survival times of cyclin D1-positive cases
also tended to be poorer than those of cyclin D1-negative cases. Multivariate analyses revealed cdc2 as the second most significant
of the prognostic variables, following lymph node status. The three-year relapse-free survival rate of cdc2/cyclin D1-double
positive cases was 58.9%, whereas that of cdc2/cyclin D1-double negative cases was 100%. Cdc2 and cyclin D1 represent the
status of cell proliferation in breast cancer, and may be useful in breast cancer assessment. 相似文献